A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial

A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial

Abstract Background Current guidelines for the management of bronchiectasis (BE) highlight the lack of evidence to recommend mucoactive agents, such as hypertonic saline (HTS) and carbocisteine, to aid sputum removal as part of standard care. We hypothesise that mucoactive agents (HTS or carbocistei...

Full description

Bibliographic Details
Main Authors: Judy Martina Bradley, Rohan Anand, Brenda O’Neill, Kathryn Ferguson, Mike Clarke, Mary Carroll, James Chalmers, Anthony De Soyza, Jamie Duckers, Adam T. Hill, Michael R. Loebinger, Fiona Copeland, Evie Gardner, Christina Campbell, Ashley Agus, Alistair McGuire, Roisin Boyle, Fionnuala McKinney, Naomi Dickson, Danny F. McAuley, Stuart Elborn, On behalf of the CLEAR study group
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Trials
Subjects:
Clinical trial protocol
Factorial design
Bronchiectasis
Hypertonic saline
Carbocisteine
Exacerbation
Online Access:https://doi.org/10.1186/s13063-019-3766-9

Internet

https://doi.org/10.1186/s13063-019-3766-9

Similar Items